CV CARE: CardioVascular Care in PC Patients

{ "CV CARE: Cardiovascular Care in Prostate Cancer Patients", "This study is testing a program called \"CV Care\" to help manage heart and blood vessel (cardiovascular) risk factors in men with prostate cancer. The program involves two counseling sessions with an oncology nurse practitioner or physician assistant to educate you about heart disease and its risks, and to recommend ways to manage them. The goal is to make this a standard part of care for all prostate cancer patients starting androgen deprivation therapy (ADT). You may be able to join if you are a man, 18 or older, with prostate cancer and your doctor recommends at least 24 weeks of ADT. The study will look at how many participants stay in the CV Care program at 4 and 24 weeks. The current status of this study is unclear.", "design": "This interventional study plans to enroll 180 men. It is testing a behavioral intervention called the CV Care Program.", "commitments": "Participation in this study is expected to last about 6 months and includes screening, treatment visits, questionnaires, surveys, and blood and urine tests.", "compensation": "Not stated in the trial record.", "follow_up": "Participant retention in the CV Care program will be measured at 4 and 24 weeks.", }

Study design: Not specified.
What's involved: Not specified in the trial record.
Compensation: Not stated in the trial record.
Follow-up: Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

CV CARE: CardioVascular Care in PC Patients

Recruiting

NAAges 18+InterventionalHealth services

Dana-Farber Cancer Institute

~180 participants

Updated 2026-06-29 on ClinicalTrials.gov

What's tested:CV Care Program

At a glance

Recruiting sites

2 of 2 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Participant Retention Rate in CV CARE 2

Measured over Weeks 4 and 24 in CV CARE 2

Conditions

Prostate Cancer

Cardiovascular Diseases

Where it's being run

2 sites across 1 states

Massachusetts2

Study leadership

Alicia Morgans, MD, MPH · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute

Who to contact

Alicia Morgans, MD, MPH

[email protected]

857-215-1605

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Participants must have a histologic diagnosis of prostate adenocarcinoma. Participants with any stage of prostate cancer are eligible, as long as treatment with at least 24 weeks of ADT is recommended by their treating physician.

Participants must have been prescribed a plan for treatment with at least 24 weeks of ADT, and can have received up to 12 weeks of ADT therapy.

Participants must be willing to participate in two CV CARE visits at weeks 12 and 24 after ADT initiation.

Participants must be willing to have their follow up visits for ADT management at DFCI Longwood site.

Participants must be willing to undergo lab and blood pressure assessments, which can include local labs and home blood pressure checks if they wish to do virtual visits for follow up care.

Participants can have pre-existing CVD and/or CV risk factors, but this is not a requirement for inclusion.

Participants receiving combination treatment with an androgen receptor signaling inhibitory, some examples being (abiraterone acetate, enzalutamide, darolutamide, apalutamide, or bicalutamide), immunotherapy (pembrolizumab), or PARP inhibitor (olaparib, rucaparib) are eligible.

Age ≥18 years.

Life expectancy of greater than 6 months.

Ability to understand and the willingness to sign a written informed consent document.

Exclusion

History of major adverse cardiac event, including myocardial infarction, new congestive heart failure (CHF) or CHF exacerbation, or stroke, within the past 24 weeks due to complicated comorbidities that necessitate close collaboration between the participant and their cardiologist.

Participants who have already been on ADT therapy for more than 12 weeks are ineligible due to their treatment cycle being incompatible with the quality improvement initiative's trial design. ADT therapy is defined as either a GnRH agonist or antagonist.

Participants receiving combination treatment with ADT and chemotherapy (docetaxel, cabazitaxel, carboplatin), radioligand therapy (radium-223, 177PSMA-lutetium-617), or treatment on a clinical trial are not eligible due to potential for more intensive symptom management that may be required for optimal support of their cancer-directed treatment.

Participants actively included in therapeutic clinical trials are not eligible due to their greater time constraints.

What this trial measures

Participant Retention Rate in CV CARE 2Weeks 4 and 24 in CV CARE 2
The percentage of a continued participation rate at week 24 of participants who participate at week 4 in the revised iteration of the program (CV CARE 2).

Trialytics